2019 LICAGE意见术:肝硬化患者围手术期止血管理

2019-07-02 外国肝病科相关专家小组(统称) Minerva Anestesiol. 2019 Jul;85(7):782-798.

2019年7月,欧洲肝脏重症监护组(LICAGE)发布了肝硬化患者围手术期止血管理意见书,旨在概述慢性肝病患者围手术期的凝血管理,包括患者血液管理、止血监测和止血剂的现状。

中文标题:

2019 LICAGE意见术:肝硬化患者围手术期止血管理

英文标题:

Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE).

发布日期:

2019-07-02

简要介绍:

2019年7月,欧洲肝脏重症监护组(LICAGE)发布了肝硬化患者围手术期止血管理意见书,旨在概述慢性肝病患者围手术期的凝血管理,包括患者血液管理、止血监测和止血剂的现状。

 

拓展指南:肝硬化相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 LICAGE意见术:肝硬化患者围手术期止血管理)] GetToolGuiderByIdResponse(projectId=1, id=77dde1c00180a1e4, title=2019 LICAGE意见术:肝硬化患者围手术期止血管理, enTitle=Perioperative hemostatic management in the cirrhotic patient: a position paper on behalf of the Liver Intensive Care Group of Europe (LICAGE)., guiderFrom=Minerva Anestesiol. 2019 Jul;85(7):782-798., authorId=null, author=, summary=2019年7月,欧洲肝脏重症监护组(LICAGE)发布了肝硬化患者围手术期止血管理意见书,旨在概述慢性肝病患者围手术期的凝血管理,包括患者血液管理、止血监测和止血剂的现状。 , cover=, journalId=null, articlesId=null, associationId=687, associationName=外国肝病科相关专家小组(统称), associationIntro=外国的关于肝病方面制定者的统称, copyright=0, guiderPublishedTime=Tue Jul 02 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019年7月,欧洲肝脏重症监护组(LICAGE)发布了肝硬化患者围手术期止血管理意见书,旨在概述慢性肝病患者围手术期的凝血管理,包括患者血液管理、止血监测和止血剂的现状。 </P> <P> </P>拓展指南:<strong>与<font color=red>肝硬化</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=1f8261c0018036fd" title="《2019年欧洲肝脏重症监护组专家共识:肝硬化患者围手术期止血管理》摘译" target=_blank>《2019年欧洲肝脏重症监护组专家共识:肝硬化患者围手术期止血管理》摘译</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ea4fa1c001ea73da" title="肝硬化患者肝切除术后肝功能不全的预防与治疗专家共识(2019版)" target=_blank>肝硬化患者肝切除术后肝功能不全的预防与治疗专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5a0be1c00169355f" title="2018 中国肝硬化腹水及相关并发症的管理指南-英文版" target=_blank>2018 中国肝硬化腹水及相关并发症的管理指南-英文版</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8d2b21c0016518be" title="肝硬化肝性脑病诊疗指南" target=_blank>肝硬化肝性脑病诊疗指南</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=cf74f1c001618976" title="欧洲失代偿期肝硬化并发症管理指南简介" target=_blank>欧洲失代偿期肝硬化并发症管理指南简介</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E8%82%9D%E7%A1%AC%E5%8C%96" target=_blank>有关肝硬化更多指南</a></ul>, tagList=[TagDto(tagId=492, tagName=肝硬化), TagDto(tagId=95582, tagName=围手术期止血管理)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7079, appHits=169, showAppHits=0, pcHits=4989, showPcHits=2777, likes=76, shares=9, comments=6, approvalStatus=1, publishedTime=Mon Oct 14 22:15:57 CST 2019, publishedTimeString=2019-07-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Oct 14 22:15:57 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 04:48:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 LICAGE意见术:肝硬化患者围手术期止血管理)])
2019 LICAGE意见术:肝硬化患者围手术期止血管理
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1061951, encodeId=23f0106195158, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:56:16 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061936, encodeId=207010619369c, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:53:58 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061892, encodeId=e5f01061892a9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:41:07 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    非常好的文章,受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1061951, encodeId=23f0106195158, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:56:16 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061936, encodeId=207010619369c, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:53:58 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061892, encodeId=e5f01061892a9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:41:07 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    非常好的文章,受益匪浅。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1061951, encodeId=23f0106195158, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:56:16 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061936, encodeId=207010619369c, content=非常好的文章,受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:53:58 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061892, encodeId=e5f01061892a9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 16:41:07 CST 2021, time=2021-10-19, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    不错

    0